Sabin Vaccine Institute

Vaccine Research & DevelopmentThe Sabin Vaccine Institute supports innovative technologies and approaches in vaccine research and development to combat infectious and emerging threats to global health. Sabin's Research & Development strategy is to prioritize strong vaccine candidates that lack commercial value, targeting diseases that impact the world's most vulnerable populations. Sabin leverages the expertise of partners in the academic, public, and private sectors, and promotes open-source research.Ebola has taken the lives of nearly 14,000 people during the last decade. To protect communities across the globe from the critical threat posed by Ebola and the closely related, but lesser known, Marburg virus, Sabin is currently developing vaccines for Sudan ebolavirus and Marburg virus diseases based on technology licensed from GSK. The prophylactic vaccine candidates are based on GSK's proprietary ChAd3 platform. In 2019, the U.S. Health and Human Services' Biomedical Advanced Research and Development Authority awarded Sabin a multi-year development contract to advance development of the Marburg and Sudan ebolavirus vaccines

Global ImmunizationDespite scientific advances and international support, 1.5 million people still die each year from diseases that could have been prevented by immunization. Sabin's Global Immunization arm focuses on improving vaccine distribution, increasing uptake, and driving more equitable access to vaccination services. Sabin works on these goals with a multi-layered programmatic approach including: advancing research to understand the social and behavioral drivers for vaccine acceptance and demand; fostering peer to peer collaboration on immunization and building capacity and leadership skills for immunization professionals; coalescing multi-sectoral partners and community leaders and influencers to support the introduction and expansion of new and under-utilized vaccines such as the HPV vaccine; and generating essential epidemiological data to inform immunization policy and implementation decisions for diseases such as typhoid.